Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Share-based Compensation (2016 - 2025)

vTv Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 24.24% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $3.8 million, up 36.92%, while the annual FY2025 figure was $3.8 million, 36.92% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.0 million at vTv Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.0 million in Q4 2025 and bottomed at $167000.0 in Q2 2022.
  • The 5-year median for Share-based Compensation is $463000.0 (2021), against an average of $586900.0.
  • The largest annual shift saw Share-based Compensation plummeted 70.72% in 2022 before it skyrocketed 269.55% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $994000.0 in 2021, then tumbled by 70.72% to $291000.0 in 2022, then skyrocketed by 38.49% to $403000.0 in 2023, then skyrocketed by 104.71% to $825000.0 in 2024, then increased by 24.24% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Share-based Compensation are $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $930000.0 (Q2 2025).